8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Feb 26, 2026·SEC
Material company update
Nov 6, 2025·SEC
Puma Biotechnology, Inc.(PBYI)Earnings, Financials & Key Ratios
PBYI•NASDAQ
$7.96
13.0× P/E·Price updated Jul 7, 2026
AboutPuma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.Show more
- Revenue$228M-0.9%
- EBITDA$48M+13.5%
- Net Income$31M+2.8%
- EPS (Diluted)0.61-1.6%
- Gross Margin74.53%+3.4%
- EBITDA Margin21.12%+14.6%
- Operating Margin16.33%+21.6%
- Net Margin13.62%+3.7%
- ROE27.97%-32.8%
PBYI Price & Volume
Puma Biotechnology, Inc. (PBYI) stock price & volume — 10-year historical chart
Loading chart...
Stagnant Revenue Growth Masks Persistent Liquidity Risks
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Strained
Financial:Vulnerable
Cash Flow:Mixed
Primary Risk:Single-asset commercial stagnation
Key Thesis Takeaways
- Puma Biotechnology faces a challenging outlook as its single-asset commercial model struggles with inconsistent patient demand, evidenced by a 2.6% year-over-year revenue decline in 2026Q1.
- While the company has successfully reduced total debt from $111.5 million in 2023Q4 to $16.0 million in 2026Q1, this deleveraging has occurred alongside a significant contraction in cash reserves.
- Investors should remain cautious as the firm's reliance on a single oncology asset and limited operating leverage may hinder future pipeline development and long-term financial stability.
Verdict Logic
the company's inability to sustain revenue growth, evidenced by the 2.6% decline in 2026Q1, combined with a dwindling cash balance of $29.6 million, suggests significant operational and liquidity risks.
PBYI Growth Metrics
Puma Biotechnology, Inc. (PBYI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years0.29%
3 Years0.05%
TTM-2.38%
Profit CAGR
10 Years-
5 Years-
3 Years2396.29%
TTM-35.94%
EPS CAGR
10 Years-
5 Years-
3 Years210.89%
TTM-37.82%
Return on Capital
10 Years-34.53%
5 Years19.47%
3 Years26.06%
Last Year29.57%
PBYI Recent Earnings
Puma Biotechnology, Inc. (PBYI) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.04+69.2%
$0.13
Rev
$45M+6.7%
$42M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.29+20.8%
$0.24
Rev
$60M-12.7%
$69M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.21+133.3%
$0.09
Rev
$54M-20.6%
$69M
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.15+36.4%
$0.11
Rev
$52M+2.8%
$51M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.04vs $0.13+69.2% | $45Mvs $42M+6.7% |
| Q1 2026 | Feb 26, 2026 | $0.29vs $0.24+20.8% | $60Mvs $69M-12.7% |
| Q4 2025 | Nov 6, 2025 | $0.21vs $0.09+133.3% | $54Mvs $69M-20.6% |
| Q3 2025 | Aug 7, 2025 | $0.15vs $0.11+36.4% | $52Mvs $51M+2.8% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Puma Biotechnology, Inc. (PBYI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $7.96 | $405.16M | 13.05 | -0.91% | 13.62% | 27.97% | — | |
| $30.25 | $3.05B | -9.19 | -4.26% | -156.36% | -68.97% | — | |
| $53.52 | $8.19B | 19.32 | 87.32% | 65.95% | 87.36% | — | |
| $89.20 | $7.4B | 11.47 | 114.51% | -22.58% | — | — | |
| $26.20 | $4.49B | 11.44 | 11.87% | 34.3% | 35.65% | — | |
| $57.08 | $14.5B | 20.53 | 6.98% | 35.08% | 40.21% | — |
Compare PBYI vs Peers
Puma Biotechnology, Inc. (PBYI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PBYI SEC Filings & Documents
Puma Biotechnology, Inc. (PBYI) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when PBYI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PBYI Frequently Asked Questions
Puma Biotechnology, Inc. (PBYI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Puma Biotechnology, Inc.'s revenue?
Puma Biotechnology, Inc. (PBYI) reported $227.2M in revenue for fiscal year 2025.
How fast is Puma Biotechnology, Inc. growing?
Puma Biotechnology, Inc. (PBYI) saw revenue decline by 0.9% over the past year.
Is PBYI profitable?
Yes, Puma Biotechnology, Inc. (PBYI) is profitable, generating $24.4M in net income for fiscal year 2025 (13.6% net margin).
Dividend & Returns
What is PBYI's return on equity?
Puma Biotechnology, Inc. (PBYI) has a return on equity (ROE) of 28.0%. This is excellent, indicating efficient use of shareholder capital.
What is Puma Biotechnology, Inc.'s free cash flow?
Puma Biotechnology, Inc. (PBYI) generated $53.6M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.